DOI:10.1016/S0140-

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer:quo vadis?

Boussios, S. (Stergios)
Moschetta, M. (Michele)
Karihtala, P. (Peeter)
Samartzis, E. P. (Eleftherios P.)
Sheriff, M. (Matin)
Pappas-Gogos, G. (George)
Ozturk, M. A. (Mehmet Akif)
Uccello, M. (Mario)
Karathanasi, A. (Afroditi)
Tringos, M. (Michail)
Rassy, E. (Elie)
Pavlidis, N. (Nicholas)

January 2020

Abstract Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women...

Profile of olaparib in the treatment of advanced ovarian cancer

Chase DM
Patel S
Shields K

April 2016

Dana M Chase,1,2 Shreya Patel,2,3 Kristin Shields4 1Division of Gynecologic Oncology, The Universit...

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.

Konecny, GE
Kristeleit, RS

November 2016

Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombi...

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer:a proof-of-concept trial

Audeh, M. William
Carmichael, James
Penson, Richard T.
Friedlander, Michael
Powell, Bethan
Bell-McGuinn, Katherine M.
Scott, Clare
Weitzel, Jeffrey N.
Oaknin, Ana
Loman, Niklas
Lu, Karen
Schmutzler, Rita K.
Matulonis, Ursula
Wickens, Mark
Tutt, Andrew

July 2010

Background Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that indu...

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. William
Carmichael, James
Penson, Richard T.
Friedlander, Michael
Powell, Bethan
Bell-McGuinn, Katherine M.
Scott, Clare
Weitzel, Jeffrey N.
Oaknin, Ana
Loman, Niklas
Lu, Karen
Schmutzler, Rita K.
Matulonis, Ursula
Wickens, Mark
Tutt, Andrew

January 2010

Background Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that indu...

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine, Eric
Ledermann, Jonathan A
Selle, Frédéric
Gebski, Val
Penson, Richard T
Oza, Amit M
Korach, Jacob
Huzarski, Tomasz
Poveda, Andrés
Pignata, Sandro
Friedlander, Michael
Colombo, Nicoletta
Harter, Philipp
Fujiwara, Keiichi
Ray-Coquard, Isabelle
Banerjee, Susana
Liu, Joyce
Lowe, Elizabeth S
Bloomfield, Ralph
Pautier, Patricia
Vergote, Ignace

September 2017

Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2...

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Tutt, Andrew
Robson, Mark
Garber, Judy E.
Domchek, Susan M.
Audeh, M. William
Weitzel, Jeffrey N.
Friedlander, Michael
Arun, Banu
Loman, Niklas
Schmutzler, Rita K.
Wardley, Andrew
Mitchell, Gillian
Earl, Helena
Wickens, Mark
Carmichael, James

January 2010

Background Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced sy...

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.

Kaufman, Bella
Shapira-Frommer, Ronnie
Schmutzler, Rita K
Audeh, M William
Friedlander, Michael
Balmaña, Judith
Mitchell, Gillian
Fried, Georgeta
Stemmer, Salomon M
Hubert, Ayala
Rosengarten, Ora
Steiner, Mariana
Loman, Niklas
Bowen, Karin
Fielding, Anitra
Domchek, Susan M

January 2015

Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2...

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.

Fong, Peter C.
Boss, David S.
Yap, Timothy A.
Tutt, Andrew
Wu, Peijun
Mergui-Roelvink, Marja
Mortimer, Peter
Swaisland, Helen
Lau, Alan
O'Connor, Mark J.
Ashworth, Alan
Carmichael, James
Kaye, Stan B.
Schellens, Jan H. M.
de Bono, Johann S.

July 2009

Background: The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potent...

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer

Jonathan A. Ledermann
Eric Pujade-Lauraine

May 2019

Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patient...

Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer

Moore, K.
Colombo, N.
Scambia, G. (ORCID:0000-0003-2758-1063)
Kim, B. -G.
Oaknin, A.
Friedlander, M.
Lisyanskaya, A.
Floquet, A.
Leary, A.
Sonke, G. S.
Gourley, C.
Banerjee, S.
Oza, A.
González-Martín, A.
Aghajanian, C.
Bradley, W.
Mathews, C.
Liu, J.
Lowe, E. S.
Bloomfield, R.
DiSilvestro, P.

January 2018

3 years after standard treatment with surgery and platinum-based chemotherapy. The benefit of the or...

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

Domchek, Susan M
Aghajanian, Carol
Shapira-Frommer, Ronnie
Schmutzler, Rita K
Audeh, M William
Friedlander, Michael
Balmaña, Judith
Mitchell, Gillian
Fried, Georgeta
Stemmer, Salomon M
Hubert, Ayala
Rosengarten, Ora
Loman, Niklas
Robertson, Jane D
Mann, Helen
Kaufman, Bella

January 2016

The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was inves...

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Fong, Peter C.
Yap, Timothy A.
Boss, David S.
Carden, Craig P.
Mergui-Roelvink, Marja
Gourley, Charlie
De Greve, Jacques
Lubinski, Jan
Shanley, Susan
Messiou, Christina
A'Hern, Roger
Tutt, Andrew
Ashworth, Alan
Stone, John
Carmichael, James
Schellens, Jan H. M.
de Bono, Johann S.
Kaye, Stan B.

May 2010

Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using ...

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21). a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine E.
Ledermann J. A.
Selle F.
Gebski V.
Penson R. T.
Oza A. M.
Korach J.
Huzarski T.
Poveda A.
Pignata S.
Friedlander M.
Colombo N.
Harter P.
Fujiwara K.
Ray-Coquard I.
Banerjee S.
Liu J.
Lowe E. S.
Bloomfield R.
Pautier P.
Korach J.
Huzarski T.
Byrski T.
Pautier P.
Harter P.
Colombo N.
Scambia G.
Nicoletto M.
Nussey F.
Clamp A.
Penson R.
Oza A.
Poveda Velasco A.
Rodrigues M.
Lotz J. -P.
Selle F.
Ray-Coquard I.
Provencher D.
Prat Aparicio A.
Vidal Boixader L.
SCOTT, STEPHEN PETER CARLO
Tamura K.
Yunokawa M.
Lisyanskaya A.
Medioni J.
Pecuchet N.
Dubot C.
de la Motte Rouge T.
Kaminsky M. -C.
Weber B.
Lortholary A.
Parkinson C.
Ledermann J.
WILLIAMS, CAROLYN S.
Banerjee S.
Cosin J.
Hoffman J.
Penson R.
Plante M.
Covens A.
Sonke G.
Joly F.
Floquet A.
Banerjee S.
Hirte H.
Amit A.
Park-Simon T. -W.
Matsumoto K.
Tjulandin S.
Kim J. H.
Gladieff L.
Sabbatini R.
O'Malley D.
Timmins P.
Kredentser D.
Lainez Milagro N.
Barretina Ginesta M. P.
Tibau Martorell A.
Gomez de Liano Lista A.
Ojeda Gonzalez B.
Mileshkin L.
Mandai M.
Boere I.
Ottevanger P.
Nam J. -H.
Filho E.
Hamizi S.
Cognetti F.
Warshal D.
Dickson-Michelson E.
Kamelle S.
McKenzie N.
RODRIGUEZ CASTILLO, GUILLERMO ANDRES
Armstrong D.
Chalas E.
Celano P.
Behbakht K.
Davidson S.
Welch S.
Helpman L.
Fishman A.
Bruchim I.
Sikorska M.
Slowinska A.
Rogowski W.
Bidzinski M.
Spiewankiewicz B.
Casado Herraez A.
Mendiola Fernandez C.
Gropp-Meier M.
Saito T.
Takehara K.
Enomoto T.
Watari H.
Choi C. H.
Kim B. -G.
Kim J. W.
Hegg R.
Vergote I.

January 2017

Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy i...

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Pujade-Lauraine, E
Ledermann, JA
Selle, F
Gebski, V
Penson, RT
Oza, AM
Korach, J
Huzarski, T
Poveda, A
Pignata, S
Friedlander, M
Colombo, N
Harter, P
Fujiwara, K
Ray-Coquard, I
Banerjee, S
Liu, J
Lowe, ES
Bloomfield, R
Pautier, P
SOLO2/ENGOT-Ov21 investigators

September 2017

Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy i...

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer:quo vadis?

Boussios, S. (Stergios)
Moschetta, M. (Michele)
Karihtala, P. (Peeter)
Samartzis, E. P. (Eleftherios P.)
Sheriff, M. (Matin)
Pappas-Gogos, G. (George)
Ozturk, M. A. (Mehmet Akif)
Uccello, M. (Mario)
Karathanasi, A. (Afroditi)
Tringos, M. (Michail)
Rassy, E. (Elie)
Pavlidis, N. (Nicholas)

January 2020

Abstract Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women...

Profile of olaparib in the treatment of advanced ovarian cancer

Chase DM
Patel S
Shields K

April 2016

Dana M Chase,1,2 Shreya Patel,2,3 Kristin Shields4 1Division of Gynecologic Oncology, The Universit...

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.

Konecny, GE
Kristeleit, RS

November 2016

Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombi...

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer:a proof-of-concept trial

Audeh, M. William
Carmichael, James
Penson, Richard T.
Friedlander, Michael
Powell, Bethan
Bell-McGuinn, Katherine M.
Scott, Clare
Weitzel, Jeffrey N.
Oaknin, Ana
Loman, Niklas
Lu, Karen
Schmutzler, Rita K.
Matulonis, Ursula
Wickens, Mark
Tutt, Andrew

July 2010

Background Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that indu...

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. William
Carmichael, James
Penson, Richard T.
Friedlander, Michael
Powell, Bethan
Bell-McGuinn, Katherine M.
Scott, Clare
Weitzel, Jeffrey N.
Oaknin, Ana
Loman, Niklas
Lu, Karen
Schmutzler, Rita K.
Matulonis, Ursula
Wickens, Mark
Tutt, Andrew

January 2010

Background Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that indu...

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine, Eric
Ledermann, Jonathan A
Selle, Frédéric
Gebski, Val
Penson, Richard T
Oza, Amit M
Korach, Jacob
Huzarski, Tomasz
Poveda, Andrés
Pignata, Sandro
Friedlander, Michael
Colombo, Nicoletta
Harter, Philipp
Fujiwara, Keiichi
Ray-Coquard, Isabelle
Banerjee, Susana
Liu, Joyce
Lowe, Elizabeth S
Bloomfield, Ralph
Pautier, Patricia
Vergote, Ignace

September 2017

Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2...

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Tutt, Andrew
Robson, Mark
Garber, Judy E.
Domchek, Susan M.
Audeh, M. William
Weitzel, Jeffrey N.
Friedlander, Michael
Arun, Banu
Loman, Niklas
Schmutzler, Rita K.
Wardley, Andrew
Mitchell, Gillian
Earl, Helena
Wickens, Mark
Carmichael, James

January 2010

Background Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced sy...

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.

Kaufman, Bella
Shapira-Frommer, Ronnie
Schmutzler, Rita K
Audeh, M William
Friedlander, Michael
Balmaña, Judith
Mitchell, Gillian
Fried, Georgeta
Stemmer, Salomon M
Hubert, Ayala
Rosengarten, Ora
Steiner, Mariana
Loman, Niklas
Bowen, Karin
Fielding, Anitra
Domchek, Susan M

January 2015

Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2...

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.

Fong, Peter C.
Boss, David S.
Yap, Timothy A.
Tutt, Andrew
Wu, Peijun
Mergui-Roelvink, Marja
Mortimer, Peter
Swaisland, Helen
Lau, Alan
O'Connor, Mark J.
Ashworth, Alan
Carmichael, James
Kaye, Stan B.
Schellens, Jan H. M.
de Bono, Johann S.

July 2009

Background: The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potent...

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer

Jonathan A. Ledermann
Eric Pujade-Lauraine

May 2019

Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patient...

Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer

Moore, K.
Colombo, N.
Scambia, G. (ORCID:0000-0003-2758-1063)
Kim, B. -G.
Oaknin, A.
Friedlander, M.
Lisyanskaya, A.
Floquet, A.
Leary, A.
Sonke, G. S.
Gourley, C.
Banerjee, S.
Oza, A.
González-Martín, A.
Aghajanian, C.
Bradley, W.
Mathews, C.
Liu, J.
Lowe, E. S.
Bloomfield, R.
DiSilvestro, P.

January 2018

3 years after standard treatment with surgery and platinum-based chemotherapy. The benefit of the or...

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.

Domchek, Susan M
Aghajanian, Carol
Shapira-Frommer, Ronnie
Schmutzler, Rita K
Audeh, M William
Friedlander, Michael
Balmaña, Judith
Mitchell, Gillian
Fried, Georgeta
Stemmer, Salomon M
Hubert, Ayala
Rosengarten, Ora
Loman, Niklas
Robertson, Jane D
Mann, Helen
Kaufman, Bella

January 2016

The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was inves...

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Fong, Peter C.
Yap, Timothy A.
Boss, David S.
Carden, Craig P.
Mergui-Roelvink, Marja
Gourley, Charlie
De Greve, Jacques
Lubinski, Jan
Shanley, Susan
Messiou, Christina
A'Hern, Roger
Tutt, Andrew
Ashworth, Alan
Stone, John
Carmichael, James
Schellens, Jan H. M.
de Bono, Johann S.
Kaye, Stan B.

May 2010

Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using ...

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21). a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine E.
Ledermann J. A.
Selle F.
Gebski V.
Penson R. T.
Oza A. M.
Korach J.
Huzarski T.
Poveda A.
Pignata S.
Friedlander M.
Colombo N.
Harter P.
Fujiwara K.
Ray-Coquard I.
Banerjee S.
Liu J.
Lowe E. S.
Bloomfield R.
Pautier P.
Korach J.
Huzarski T.
Byrski T.
Pautier P.
Harter P.
Colombo N.
Scambia G.
Nicoletto M.
Nussey F.
Clamp A.
Penson R.
Oza A.
Poveda Velasco A.
Rodrigues M.
Lotz J. -P.
Selle F.
Ray-Coquard I.
Provencher D.
Prat Aparicio A.
Vidal Boixader L.
SCOTT, STEPHEN PETER CARLO
Tamura K.
Yunokawa M.
Lisyanskaya A.
Medioni J.
Pecuchet N.
Dubot C.
de la Motte Rouge T.
Kaminsky M. -C.
Weber B.
Lortholary A.
Parkinson C.
Ledermann J.
WILLIAMS, CAROLYN S.
Banerjee S.
Cosin J.
Hoffman J.
Penson R.
Plante M.
Covens A.
Sonke G.
Joly F.
Floquet A.
Banerjee S.
Hirte H.
Amit A.
Park-Simon T. -W.
Matsumoto K.
Tjulandin S.
Kim J. H.
Gladieff L.
Sabbatini R.
O'Malley D.
Timmins P.
Kredentser D.
Lainez Milagro N.
Barretina Ginesta M. P.
Tibau Martorell A.
Gomez de Liano Lista A.
Ojeda Gonzalez B.
Mileshkin L.
Mandai M.
Boere I.
Ottevanger P.
Nam J. -H.
Filho E.
Hamizi S.
Cognetti F.
Warshal D.
Dickson-Michelson E.
Kamelle S.
McKenzie N.
RODRIGUEZ CASTILLO, GUILLERMO ANDRES
Armstrong D.
Chalas E.
Celano P.
Behbakht K.
Davidson S.
Welch S.
Helpman L.
Fishman A.
Bruchim I.
Sikorska M.
Slowinska A.
Rogowski W.
Bidzinski M.
Spiewankiewicz B.
Casado Herraez A.
Mendiola Fernandez C.
Gropp-Meier M.
Saito T.
Takehara K.
Enomoto T.
Watari H.
Choi C. H.
Kim B. -G.
Kim J. W.
Hegg R.
Vergote I.

January 2017

Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy i...

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Pujade-Lauraine, E
Ledermann, JA
Selle, F
Gebski, V
Penson, RT
Oza, AM
Korach, J
Huzarski, T
Poveda, A
Pignata, S
Friedlander, M
Colombo, N
Harter, P
Fujiwara, K
Ray-Coquard, I
Banerjee, S
Liu, J
Lowe, ES
Bloomfield, R
Pautier, P
SOLO2/ENGOT-Ov21 investigators

September 2017

Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy i...

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer:quo vadis?

Boussios, S. (Stergios)
Moschetta, M. (Michele)
Karihtala, P. (Peeter)
Samartzis, E. P. (Eleftherios P.)
Sheriff, M. (Matin)
Pappas-Gogos, G. (George)
Ozturk, M. A. (Mehmet Akif)
Uccello, M. (Mario)
Karathanasi, A. (Afroditi)
Tringos, M. (Michail)
Rassy, E. (Elie)
Pavlidis, N. (Nicholas)

January 2020

Abstract Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women...

Profile of olaparib in the treatment of advanced ovarian cancer

Chase DM
Patel S
Shields K

April 2016

Dana M Chase,1,2 Shreya Patel,2,3 Kristin Shields4 1Division of Gynecologic Oncology, The Universit...

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.

Konecny, GE
Kristeleit, RS

November 2016

Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombi...

DOI:10.1016/S0140-

Abstract

Extracted data

DOI:10.1016/S0140-

Abstract

Extracted data

Related items

Related items